On a mission to help the population synchronise their circadian rhythm, Galventa, the St. Gallen-based life science startup behind the first nutraceutical supplement to control the wake-up process, has secured a €696K seed investment led by the Turkish pharma firm Gen Ilac.
Galventa, which was founded in 2018 and is currently part of the Founders Factory accelerator program, will use the fresh capital to expand its team, product portfolio and scale up production of solutions utilising its innovative and clinically tested galenic platform technologies.
This includes the upcoming launch of its world-first nutraceutical product – B・SYNC ON – into European markets, such as Switzerland, Germany and the UK. Containing caffeine, vitamin B5 and B12 as well as Zinc B to reduce tiredness and boost mental performance, B・SYNC ON is a delayed release wake-up supplement that helps people wake-up naturally after a full night’s sleep with sharper focus and a positive mood.
Commenting on the capital raise, Galventa CEO and Co-Founder Sascha Fritsche stated: “This is a big milestone for Galventa. We are excited to see such great interest and trust in our innovative technology and our first nutraceutical product. After conducting first market tests we look forward to fully launching B・SYNC ON and helping the large population with wake-up difficulties.”